ERC-142 is a compound being developed for the treatment of critical limb ischemia (lack of blood supply) to improve blood supply in order to avoid tissue death and amputation.

StemCells (STEM) engages in clinical and preclinical research and development for human neural stem cells and liver engrafting cells. Earlier stage preclinical work is focused on spinal cord injuries, myelin, and retinal disorders.

BioMimetic Therapeutics (BMTI) develops regenerative medicine device/therapeutic combination products for bio-therapeutic applications for orthopedic/spine, sports medicine, and dental procedures.

RTI Biologics (RTIX) is a provider of bio-implants and grafts to promote healing and repair for orthopedic/spinal applications, sports medicine, bone graft substitutes, and cardiovascular applications.

Cytori Therapeutics (CYTX) is a commercial-stage regenerative medicine company which is developing the Celution System to process a patient's own fat (adipose) tissue in about one hour for a variety of reconstructive and cosmetic medicine therapeutic applications.

CYTX also offers StemSource Cell Banking for a patient to preserve their own adipose-derived stem + regenerative cells (ADRCs) for use in the future as ongoing clinical trials establish the safety and effectiveness for cardiovascular disease, breast reconstruction/augmentation, liver disease, kidney failure, orthopedic/spinal disc regeneration, and gastrointestinal disorders.

CYTX currently offers its products and services in Japan and Europe along with two key strategic partners – Olympus Corp. (OCPNY.PK) (a strategic investor + medical device partner for Celution System) and Green Hospital Supply (GHSPF.PK) (a strategic investor + partner for StemSource Cell Banking, initially targeting hospitals in Japan).

Aastrom Biosciences (ASTM) is developing autologous (derived from the patient) cell products for the repair and regeneration of human tissue. Aastrom's Tissue Repair Cell (TRC) technology utilizes a patient's own bone marrow as the source of progenitor and stem cells for use in cardiac and vascular tissue regeneration.

Mesoblast (MBLTY.PK) (Australia: MSB.AX) is an adult stem cell company focused on commercializing RepliCart for bone and cartilage repair and regeneration, with recent approval to conduct a Phase 2 clinical trial for knee osteoarthritis. Mesoblast also has a U.S. subsidiary focused on cardiovascular applications for its regenerative medicine technology.

BioTime (BTIM.OB) offers blood plasma expanders such as Hextend along with its Embryome Sciences subsidiary, which includes 11 new cell lines that will be marketed to universities and bio-pharma companies for use in research programs focused on developing new cell-based therapies for neurodegenerative disease, muscular dystrophy, heart disease, cancer, and arthritis, as well as other potential applications in the emerging field of regenerative medicine.

Osteotech (OSTE) provides OsteoBiologic solutions for regenerative medicine applications to repair and replace bone loss caused by trauma or disease, augment prosthetic implant procedures, facilitate spinal fusion, and replace/repair damaged ligaments and tendons.

Neuralstem (CUR) manufactures human neural stem cells for research grant and collaborative programs and outsources the manufacturing and storage of its stem cells for use in pre-clinical studies to Charles River Labs (CRL).

RegeneRx Biopharma (RGN) has developed three drug product candidates based on a peptide molecule (Thymosin beta 4), which demonstrates promise for a variety of tissue and organ repair applications. RGN-137 is a topical gel product for healing chronic dermal wounds. RGN-259 is an eye drop for ophthalmic injuries. RGN-352 is an injectable treatment for heart attacks.

ThermoGenesis (KOOL) is a commercial-stage provider of systems for the storage and processing of adult stem cells derived from cord blood and bone marrow. KOOL offers the AutoXpress Platform (AXP) (cord blood processing) as a family of automated devices which includes the MarrowXpress (bone marrow processing) and related disposables as a closed system to process and collect adult stem cells.

The CryoSeal FS System produces fibrin sealants from blood in about one hour for use in liver resection surgeries.